BASF and Bend Research have signed an agreement to evaluate and develop excipients to enhance the solubility and bioavailability of poorly soluble drugs. The collaboration aims to meet increasing challenges of poorly soluble APIs (BCS Class II and IV compounds). The initial focus will be on optimizing new vinylpyrrolidone based copolymers being developed for the solubilization of poorly soluble APIs.
BASF will provide its expertise in ingredient formulation and material science and its excipient products, while Bend Research with utilize its formulation development technology in the field of spray drying and hot-melt extrusion.
"We are excited about the opportunities this collaboration brings to us and our customers," said Rod Ray, chief executive officer of Bend Research. "It offers early access to a different set of chemistries and allows us to develop and test customer formulations based on new polymers. BASF has an impressive track record developing and launching novel excipients. This deal complements our recently announced collaboration on cellulosics, because it gives us access to completely different chemistries."
"We are glad to bring our in-depth knowledge of polymeric excipients into this collaboration to jointly extend the current toolbox already comprising innovations like Soluplus,” said Ralf Fink, vice president global marketing at BASF Pharma Ingredients & Services business unit. “Coupled with Bend Research’s outstanding strengths in formulation development, including spray-drying and hot-melt extrusion, we are in a unique position to address urgent solubility challenges. With this partnership, we help our customers with the development of drugs with poor bioavailability."